The study is carried out by one of the few students of the Institute of Biomedical Sciences (ICB-USP), University of Sao Paulo, under the guidance of Professor Lucio Freitas-Junior. The project is funded by the State of Sao Paulo (Fapesp).
. Human cells infected with Chikungunya virus were treated with sofosbuvir and the drug eliminated the virus without damaging the cells.
Freitas-Junior, a researcher, stressed that sofosbuvir is already an approved drug for human use and greatly reduces the time it takes to treat chikungunya. it was predicted to do so.
"Sofosbuvir is a medicine that has already passed the approval process for human use, allowing Chikungunya to be used for a period of one to three years." The cost of clinical trials calculated from $ 500,000 will be much lower. He also said, "Freitas-Junior.
The researcher recalled that the chikungunya caused a serious illness only because of the acute attack, but because of sequelae that could cause joint pains that may disturb the infected individuals for months or years.
Chikungunya, dengue, Zika, and yellow are one of the viruses that are responsible for transmitting fever and are transmitted by the bite of the Aedes aegypti mosquito, which produces symptoms similar to dengue in the acute phase. head and muscle, fever or nausea.
"Sofosbuvir is a special element that can become a powerful tool to fight against this virus." The results of our research allow relevant institutions to initiate clinical trials, "explains Freitas-Junior.
This finding is also important for public health because researchers point out that in the next two years there will be a disease outbreak of a virus released in Brazil by rebounds in yellow fever cases this year. According to this study, according to a study that the same researchers will publish an article soon.
Chikunguña was the disease that was transmitted by the most deadly Aedes aegypti in Brazil in 2017 and was still approved by the vaccine or a specific drug. EFE